FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for migaldendranib for the treatment of wet age-related macular degeneration and diabetic macular edema.
The subcutaneous injection is a tyrosine kinase inhibitor designed to block all forms of VEGF, Singer explained at the Retina World Congress. A study investigated migaldendranib (Ashvattha Therapeutics) given monthly and every 2 weeks.
“This is the first potential at-home monthly therapy that can be used either alone or in combination with intravitreal anti-VEGF medicines